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Abstract
Objective. The aim of this study was to compare the estimated glomerular filtration rate (GFR) using the Cockcroft-Gault
and the 4-, 5-, and 6-variable Modification of Diet in Renal Disease (MDRD) formulas for digoxin dose adjustment.
Methods. Steady-state serum digoxin concentrations were determined in 100 patients with heart failure and normal to
severely impaired renal function. Total clearance (CL) and predicted average concentrations of digoxin were calculated
using general pharmacokinetic principles.
Results. The mean9SEM (median) estimated GFR values were 48.992.8 (46.5) mL/min/1.73 m
2 using the Cockcroft-
Gault formula, 61.493.6 (56.4) mL/min/1.73 m
2 using the MDRD4 formula, 56.893.3 (52.1) mL/min/1.73 m
2 using the
MDRD5 formula, and 53.393.0 (48.7) mL/min/1.73 m
2 using the MDRD6 formula, with high correlation coefficients
between the estimates (r]0.928, PB0.001). Significant correlations were found between the digoxin total CL and
estimated GFR by the Cockcroft-Gault (r 0.649, PB0.001), MDRD4 (r 0.634, PB0.001), MDRD5 (r 0.635, PB
0.001), and MDRD6 (r 0.652, PB0.001) formulas. A significant negative correlation of the digoxin total CL/GFR ratio
with estimated GFR was obtained (r  0.356, PB0.001), with a high variability for this ratio for GFR lower than 60 mL/
min. Analogous correlation coefficients were found between the obtained and predicted digoxin concentrations calculated
using the estimated GFR by the Cockcroft-Gault (r 0.628, PB0.001), MDRD4 (r 0.642, PB0.001), MDRD5 (r 
0.650, PB0.001), and MDRD6 (r 0.665, PB0.001) formulas, with a wide dispersion between the values in all cases.
Conclusion. For GFR lower than 60 mL/min, the high interindividual variation of the digoxin total CL found among patients
with similar renal function is an important limiting factor in the prediction of digoxin dosage regimens.
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Digoxin has been used in therapeutics for more than
two centuries; however, considering its economic
and clinical benefits and its easy availability through-
out the world, it should not be considered a drug of
the past, with current approved uses for treating
atrial fibrillation, with or without heart failure, and
heart failure, with or without systolic dysfunction
(1). The accepted therapeutic range for serum
digoxin has changed in the past few years, and while
the trough level of 2.0 mg/L is still useful in helping
with the diagnosis of toxicity, at present it seems
clear that digoxin should be administered in a dose
to reach serum levels between 0.5 and 1.2 mg/L
(1,2). The toxicity of this cardiac glycoside is dose-
dependent, and as a substantial fraction of the
absorbed dose is cleared by the kidneys, its toxicity
is often the result of impaired renal function (1).
Glomerular filtration rate (GFR) is considered as
the best measurement of kidney function, and its
determination is important for drug dosage adjust-
ment (3,4). GFR is currently estimated in clinical
practice using different formulas based on serum
creatinine, and the Cockcroft-Gault equation (5) is
the most commonly used in pharmacokinetic studies
and in the guidance of drug dosing. In an attempt to
provide a more accurate estimate of GFR, the data
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(MDRD) study have been analysed and MDRD
equations derived (6,7). It has been suggested that in
most cases the GFR estimates from the Cockcroft-
Gault and MDRD equations fall within the same
interval for drug dose adjustment (8); however,
discordant results have been obtained in different
comparison studies (9 16).
The aim of our study was to compare GFR
estimation from serum creatinine using the Cock-
croft-Gault and the 4-, 5-, and 6-variable MDRD
formulas in relation to therapeutic digoxin monitor-
ing in patients with heart failure and normal to
severely impaired renal function.
Patients and methods
A group of 100 patients (43 male, 57 female) with a
mean age (9SEM) of 79.490.8 years (range 47 
94 years) with cardiac insufficiency was studied.
They were given digoxin orally in tablet form in
doses that had not been changed for at least 20 days
beforehand, of between 0.125 and 0.25 mg/24 48 h.
The blood samples were taken once the distribution
stage was complete 24 48 hours after the last dose
and correspond to the trough steady-state digoxin
concentrations. The study was carried out accor-
ding to the good practice rules for investigation in
humans of the Consellerı ´a de Sanidade (Regional
Ministry of Health) of the Xunta de Galicia, Spain.
Serum digoxin concentrations were determined
by fluorescence polarization immunoassay in an
Abbott TDx analyser using reagents from Abbott
Laboratories (Abbott Park, IL, USA). The determi-
nation of serum creatinine, urea, and albumin was
carried out in an Advia 2400 Chemistry System
(Siemens Health Care Diagnostics Inc., Newark,
DE, USA). The estimated GFR values from serum
creatinine were calculated in accordance with the
Cockcroft-Gault (5), and the 4-variable (age, sex,
race, and serum creatinine) (MDRD4), 5-variable
(age, sex, race, and serum creatinine and urea)
(MDRD5), and 6-variable (age, sex, race, and
serum creatinine, urea, and albumin) (MDRD6)
equations (6,7), using the National Kidney Founda-
tion GFR calculator (17). Height in the elderly is
difficult to measure accurately (9), and this fact
would introduce a misleading factor in the body
surface area (BSA) calculation; however, the esti-
mated GFR values by the Cockcroft-Gault and
MDRD formulas are, respectively, expressed in
mL/min and mL/min/1.73 m
2, and consequently,
within the context of our study, it was necessary in
some cases to adjust the Cockcroft-Gault GFR
values for the BSA of 1.73 m
2, by dividing the
estimates by BSA and multiplying by 1.73 m
2.
Inversely, the estimated GFR values using the
MDRD formulas were multiplied by the BSA and
divided by 1.73 m
2 for their expression in mL/min.
In order to calculate the digoxin total clearance (CL)
and average serum steady-state concentration (Css)
in the group of patients with heart failure studied,
the following equations were used (18):
CL (mL=min)
 (0:33 mL=kg=min) (weight in kg)
 0:9 (GFR in mL=min)( 1)
Css (S)( F)( dose=t)=CL (2)
S corresponds to the active fraction of the
administered form (1 for digoxin), F is the bioavail-
ability (0.7 for tablets), and t the dosing interval.
Statistical analysis was carried out using the
StatGraphics Plus (v. 5.0) package. The Shapiro-
Wilks method was used to check the distribution of
data, and Pearson’s correlation coefficient was used
when the data had a Gaussian distribution; other-
wise, Spearman’s correlation coefficient was used.
The regression analysis was carried out using the
Passing-Bablock non-parametric method. The com-
parison of the estimated GFR values was also carried
out using the difference plots of Eksborg (19). In
accordance with the proposed validation criteria of
analytical methods for the quantitative determina-
tion of drugs and their metabolites, the acceptance
criterion for accuracy is a deviation of no more than
15% from the nominal value (20,21). The results
were expressed as mean9SEM (median), and sta-
tistical significance was considered as PB0.05.
Results
In our group of patients, the estimated GFR values
using the Cockcroft-Gault formula (48.992.8
(46.5) mL/min/1.73 m
2) were significantly lower
(PB0.001) than those obtained using the MDRD4
(61.493.6 (56.4) mL/min/1.73m
2), MDRD5
(56.893.3 (52.1) mL/min/1.73m
2), and MDRD6
(53.393.0 (48.7) mL/min/1.73 m
2) formulas.
Figure 1 shows the correlation and regression, and
the difference plots, of the GFR values estimated by
the Cockcroft-Gault formula with those obtained
using the 4-, 5-, and 6-variable MDRD equations.
Significant negative correlations were found
between the digoxin total CL calculated from the
obtained serum digoxin concentration using Equa-
tion 2, and the serum creatinine (r  0.594,
PB0.001) and urea (r  0.547, PB0.001) con-
centrations. Analogous correlation coefficients were
found between the digoxin total CL and the GFR
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PB0.001), MDRD4 (r 0.634, PB0.001),
MDRD5 (r 0.635, PB0.001), and MDRD6 (r 
0.652, PB0.001) formulas. Significant negative
correlations were obtained between the digoxin total
CL/GFR ratio and the GFR estimated by the
Cockcroft-Gault (Figure 2) or MDRD formulas
(data not shown). As the obtained trough rather
than average digoxin concentrations were used for its
calculation using Equation 2, the digoxin total CL
values considered in Figure 2 represent over-esti-
mates of the actual values.
In the group of patients studied, the obtained
serum (trough) concentration of digoxin (1.589
0.11 (1.25) mg/L) was significantly lower (PB
0.001), with a deviation of more than 15%, than
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Figure 1. Correlation and regression (A, C, E) and Eksborg difference plots (B, D, F) between the estimated GFR values using the
Cockcroft-Gault formula and those obtained using the MDRD4, MDRD5, and MDRD6 formulas.
156 M. Vazquez-Hernandez et al.the digoxin (average) concentrations predicted by
Equation 2, in where the digoxin total CL was
calculated by means of Equation 1 and using the
GFR estimates of the Cockcroft-Gault (2.1790.10
(2.04) mg/L), MDRD4 (1.8990.09 (1.74) mg/L),
MDRD5 (1.9990.09 (1.79) mg/L), and MDRD6
(2.0690.10 (1.84) mg/L) formulas. Only the mean
(median) predicted serum digoxin concentrations
using the GFR values estimated by the Cockcroft-
Gault and MDRD4 formulas have a deviation of
more than 15% between them. Figure 3 shows the
correlation and regression found between the ob-
tained and predicted digoxin concentrations.
Discussion
A substantial fraction of the absorbed digoxin is
eliminated by the kidneys, with a renal CL approxi-
mately equal to or slightly lower than creatinine CL.
In healthy persons the metabolic CL of digoxin is
approximately 0.80 mL/min/kg, and congestive
heart failure reduces this CL to around one-half its
normal value, thereby slightly reducing the renal CL
of the drug (18).
The GFR in the elderly, older age being pre-
valent in digoxin-treated patients, remains an un-
resolved problem as no equation has been validated
in this population (9,13) and accurate measure-
ments are rarely applicable in normal clinical set-
tings. Different authors have stated that the
Cockcroft-Gault formula cannot easily be replaced
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Figure 2. Relationship between the digoxin total CL/GFR ratio
and GFR estimated by the Cockcroft-Gault formula.
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Figure 3. Correlation and regression between the obtained digoxin concentrations and those predicted calculated using the GFR estimated
by the Cockcroft-Gault (A), MDRD4 (C), MDRD5 (B), and MDRD6 (D) formulas.
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the GFR values resulting in different drug dosing
recommendations (10,11,13 16). At present, the
US Food and Drug Administration and the Kidney
Disease Outcomes Quality Initiative of the National
Kidney Foundation still recommend the use of the
Cockcroft-Gault rather than the abbreviated
MDRD formula for drug dose adjustment (15).
In our group of patients, high correlation coeffi-
cients (r]0.928) were found between the GFR
values estimated by the different formulas (Figure
1 A, C, E). In accordance with previously published
data (10,11,13 16), the mean (median) GFR value
estimated by the Cockcroft-Gault formula was
significantly lower than those obtained using the
MDRD4, MDRD5, and MDRD6 formulas (PB
0.001). However, as indicated by the difference
plots of Figure 1 (B, D, F), for GFR values lower
than 60 mL/min/1.73 m
2, the Cockcroft-Gault GFR
estimates were frequently higher than those of the
4-, 5-, and 6-variable MDRD formulas.
It has recently been suggested that the 6-variable
MDRD performs better than the Cockcroft-Gault
formula in predicting aminoglycoside CL and may
be considered as a tool for aminoglycoside-dosing
recommendations (12). The MDRD4 equation
tends to over-estimate and the Cockcroft-Gault
formula to under-estimate in subjects aged 65 or
older, and true GFR values could be situated
between these two approximate values (9). The
MDRD6 formula may comply with this requirement
and would lead to a more accurate GFR estimation.
Contrary to O’Riordan et al. in healthy volun-
teers (22), in our patients with normal to severely
impaired renal function we found a significant
negative correlation of the digoxin total CL with
serum creatinine and urea concentrations (PB
0.001). Analogous correlation coefficients were ob-
tained between the digoxin total CL and estimated
GFR using the Cockcroft-Gault or the MDRD
formulas (r]0.634, PB0.001). In line with pre-
vious studies (23), the results shown in Figure 2
demonstrate that the great interindividual variability
of the digoxin total CL/GFR ratio for GFR estimates
lower than approximately 60 mL/min is an impor-
tant limiting factor in the prediction of digoxin
dosage regimens. Although 80% of the digoxin
dose is excreted unchanged into urine in patients
with normal renal function, in cases with renal
failure the relative contribution of the hepatic
elimination is increased and may be estimated to
be as high as 75% in haemodialysis patients (24). As
a result, the increase of the interindividual variation
of the digoxin total CL, observed when GFR is lower
than 60 mL/min among patients with similar renal
function, could be attributed to differences in its
hepatic elimination, a process that may be affected
by the possible inhibition of the digoxin hepatic
uptake by uraemic toxins (25). In any event, the
possible impact of endogenous or exogenous di-
goxin-like immunoreactive substances on the com-
mercial immunoassays used in therapeutic digoxin
monitoring may be considered (26).
Analogous correlation coefficients were found
between the obtained and predicted digoxin con-
centrations calculated using the GFR estimated by
the Cockcroft-Gault or MDRD formulas (Figure 3),
and only the mean (median) of the predicted digoxin
concentrations using the Cockcroft-Gault and
MDRD4 formulas had a deviation of more than
15% between them. However, the wide dispersion
found between predicted and obtained digoxin
concentrations is the main limiting factor for the
clinical application of this predictive model. With
respect to other recently proposed predictive digoxin
dosage regimens (27), analogous considerations
would be made. Assuming that digoxin CL remains
stable in a patient, a more realistic use of Equation 2
may be to predict the steady-state digoxin concen-
tration that will be achieved at a particular dosage in
relation to the concentration previously obtained for
another dose (28).
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